A5023528069- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Chemical Synthesis and Analysis
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Antifungal resistance and susceptibility
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- COVID-19 Clinical Research Studies
- Eosinophilic Disorders and Syndromes
- Health and Medical Education
- Cell Adhesion Molecules Research
- Protein Degradation and Inhibitors
- Neuroendocrine Tumor Research Advances
- Biosimilars and Bioanalytical Methods
- Histiocytic Disorders and Treatments
- Autoimmune and Inflammatory Disorders Research
- Lung Cancer Research Studies
- Nail Diseases and Treatments
- Ubiquitin and proteasome pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
University of California, San Francisco
2020-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2021-2024
University of California System
2020-2023
Instituto Nacional de Cancerología
2016-2021
Universidad Nacional de Colombia
2016-2021
Asociación Colombiana de Hematología y Oncología
2019-2020
Asociación Colombiana de Gastroenterología
2019-2020
University Foundation
2019
Fundación Universitaria de Ciencias de la Salud
2018
Hospital Universitario Infantil San José
2018
The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define surfaceome at baseline, in drug resistance, response acute treatment. We provide a scoring system antigens identify CCR10 promising target this disease expressed widely on malignant plasma cells. engineer proof-of-principle chimeric antigen receptor (CAR) T-cells targeting using its...
Abstract Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express protein conformations are invisible to standard target discovery pipelines evaluating gene or expression, and these can be identified immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein capture ‘structural surfaceomics’. As proof...
Abstract Monoclonal antibodies (mAbs) are a central component of therapy for hematologic malignancies. Widely used mAb agents in multiple myeloma (MM) include daratumumab and elotuzumab. However, not all patients respond to these agents, resistance is significant clinical issue. A recently discovered subset human natural killer (NK) cells lacking expression FcεRIγ (g-NK cells) was found have multifold increase antibody-dependent effector functions after CD16 crosslinking. In this study, we...
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are urgent need additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target other cancers, specifically upregulated cell surface antigen high risk myeloma tumors. We use structure-guided design to define CD27-based anti-CD70 CAR-T that outperforms all tested scFv-based CARs, leading >80-fold improved...
Abstract Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as overexpressed therapeutic target in multiple developed the antibody YS5, which targets cancer-specific epitope on this protein. We further CD46-targeting PET probe [89Zr]Zr-DFO-YS5 [225Ac]Ac-DOTA-YS5 radiopharmaceutical therapy of prostate cancer. These prior studies suggested feasibility antigen theranostic myeloma. Herein,...
Abstract Introduction: CD19 CAR T-cells have markedly improved the survival of patients with B-cell malignancies. However, over half relapse after this therapy, many due to antigen loss. Our laboratory discovered CD72, a B cell specific surface widely expressed on We developed an effective humanized nanobody-based CAR-T (“H24 nanoCAR”) against target (Nix et al. Cancer Discov 2021, Temple JITC 2023) that we are moving clinical translation. observed reduced efficacy H24 nanoCAR versus tumor...
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are urgent need additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target other cancers, specifically upregulated cell surface antigen myeloma tumors. We use structure-guided design to define CD27-based anti-CD70 CAR-T that outperforms all tested scFv-based CARs, leading >80-fold improved...
Background: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, most CAR T targets it is observed that low surface density on tumors can significantly reduce therapeutic efficacy. Here, we explore this dynamic in the context of CD72, a recently found as promising target refractory B-cell cancers, but which CD72 lead to resistance preclinical models. Methods: Primary samples were accessed via institutional review...
Abstract Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder that predominantly affects infants and young children. Hematopoietic stem cell transplantation (HSCT) standard of care, but post-HSCT relapse common, highlighting the need for innovative therapies. While adoptive immunotherapy with chimeric antigen receptor (CAR) T cells has improved outcomes patients advanced lymphoid malignancies, it not been comprehensively evaluated in JMML. In present study, we use bulk...
ABSTRACT The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define markers most-enriched on when compared B-cell malignancy models, revealing unexpected biological signatures unique malignant plasma cells. We next integrate our proteomic dataset existing transcriptome databases, nominating CCR10 and TXNDC11 possible...
Niemann-Pick (NP) disease is a rare, autosomal recessive disorder characterized by visceromegaly and neurological alterations due to the excessive storage of lipids, sphingomyelin, cholesterol. It commonly affects child population, only 6% it occurs in adult population. Type A classified as acute form, type B latest with best prognosis, C alteration. The diagnosis based on enzymatic tests genetic sequencing, latter being diagnostic confirmation test. No specific treatment exists for this...
Background: Bone marrow aspiration and biopsy are diagnostic methods in the study of hematological diseases.Complications rare.Knowing morbidity mortality related to procedure is essential order implement preventive behaviors improvement plans.Objective: To determine incidence complications patients over 18 years who were undergone bone a university hospital between October 2013 May 2015.Furthermore, frequency, socio-demographic clinical characteristics established as well.Materials &...
CD38 is a glycoprotein expressed at low level in myeloid and lymphoid tissues. However, it highly homogeneously plasma cells (PC) multiple myeloma. Daratumumab human CD38-specific IgG1 antibody available for the treatment of myeloma Colombia. It has been authorized relapsed/refractory disease as front-line non-eligible stem cell transplantation patients by INVIMA (Instituto Nacional de Vigilancia Medicamentos y Alimentos) that regulatory agency. associated with negativization expression PC,...
We present the clinical case of a 29-year-old male with diagnosis chronic myeloid leukemia (CML) in high-risk phase since February 2010. He started treatment imatinib at dose 400 mg obtaining hematologic response early but without reaching cytogenetic month 18. Then, dasatinib was prescribed. The BCR-ABL transcription level 58% documented. It decided to start nilotinib March 2017 we diagnosed progression blast crisis (BC) origin bone marrow study that documented 72% blasts normal karyotype,...
For a long time, the diagnostic approach to IA/Aspergillus disease has been challenge. The definitive diagnosis is made by correct microbiological and/or histopathological documentation, undoubtedly fundamental cornerstone for therapeutic decision-making. However, it considered limited lack of sensitivity and speed, often being counterproductive, as in many cases invasive procedures are needed (e.g., fibrobronchoscopy [FBC] or tissue biopsy), which delays treatment undermines survival...
Introducción: dentro de los subtipos linfoma, el linfoma células del manto o anteriormente denominado linfocítico intermedio corresponde a 3-10% no Hodgkin B. El tratamiento se enfoca según la clasificación paciente, edad, estado funcional y comorbilidades, lo cual está directamente relacionado con capacidad recibir un intensivo trasplante. Es importante homogeneizar conductas fin ofrecer las mejores alternativas bajo contexto colombiano, pues actualmente existen diferentes opciones...